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Abstract Transdifferentiation of B cell lymphoma of
germinal center cell origin to histiocytic sarcoma has
recently been described but is a rare occurrence. The cause
for loss of B cell differentiation in these lymphomas is
unknown. We investigated whether somatic hypermutation
of the PAX-5 gene, a transcription factor that is important
for maintaining B cell identity and is frequently mutated in
B cell lymphomas of germinal center cell origin, might be a
cause for loss of PAX-5 expression and thus B cell
phenotype. However, no somatic hypermutation of the
PAX-5 gene was detected in the two cases we studied. The
molecular basis for transdifferentiation of B cell lymphoma
to histiocytic sarcoma remains therefore unresolved.
Keywords PAX-5.B-cell.Lymphoma.
Histiocyticsarcoma.Transdifferentiation
Introduction
Phagocytes are derived from monocytes that enter the blood
and migrate into tissues to differentiate into macrophages/
histiocytes [1, 2]. Tumors of histiocytes and dendritic cells
are extremely rare and their classification is still controver-
sial [1, 2]. In the last World Health Organization classifi-
cation [1], primary histiocytic sarcoma (HS) is defined as a
tumor with morphologic and immunohistochemical features
similar to those of mature histiocytes and usually lack
clonal immunoglobulin and T cell receptor genes. Of
interest, those tumors frequently occur in patients with
another malignant tumor. For example, a subset of cases
with HS occurs in patients with previously diagnosed
mediastinal germ cell tumors; other cases are associated
with malignant lymphomas [3–6].
Of interest is one recent publication which described rare
cases of HS occurring as a transformed tumor from B cell
lymphoma [7]. Here, we report two such cases and set out
to look for a mechanism explaining this transdifferentiation.
Somatic hypermutation affects rearranged immunoglob-
ulin genes in B cells and results in higher affinity of the
antibody. However, aberrant somatic hypermutation that
affects other genes, including the PAX-5 gene, has been
described in B cell lymphomas [8]. PAX-5 is a transcription
factor that is important for maintaining B cell identity [9].
We therefore investigated whether PAX-5 aberrant somatic
hypermutation was a cause of the lack of PAX-5 expression
and a probable cause of transdifferentiation.
Materials and methods
Clinical histories
Patient 1 A 53-year-old male patient was diagnosed in 1995
with stage IVA follicular lymphoma, grade 2 with generalized
lymph node and bone marrow involvement. He was treated
with chlorambucil/prednisolone for 6 months. A first relapse
was detected 7 years later and the patient was treated again.
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Oslo, NorwayAntibody (clone) Source Dilution HIER
CD45 (LCA, 2B11/PD7/26) DAKO Cytomation, Denmark A/S 1:100 LpH
CD20 (L-26) DAKO Cytomation, Denmark A/S 1:300 LpH
CD3 (SP7, rabbit monoclonal) LabVision Corporation, UK 1:150 LpH
CD79a (SP-18, rabbit monoclonal) LabVision Corporation, UK 1:400 T/E
PAX-5 (24) BD Transduction Laboratories™ 1:40 T/E
CD10 (56C6) Novocastra™ 1:40 T/E
BCL-6 (PG-B6p) DAKO Cytomation, Denmark A/S 1:40 T/E
BCL-2 (Bcl-2/100/D5) Novocastra™ 1:20 T/E
CD21 (2G9) Novocastra™ 1:20 T/E
CD68 (PG-M1) DAKO Cytomation, Denmark A/S 1:250 T/E
CD14 (7) Novocastra™ 1:160 T/E
CD1a (MTB1) Novocastra™ 1:5 T/E
PU1 (polyclonal) Santa Cruz Biotechnology 1:300 T/E
MAF-B (goat polyclonal) Santa Cruz Biotechnology 1:2000 T/E
S-100 (polyclonal) DAKO Cytomation, Denmark A/S 1:1500 LpH
Ki67 (MIB-1) DAKO Cytomation, Denmark A/S 1:150 T/E
Table 1 List of the antibodies
used for immunohistochemistry
Fig. 1 a, b Lymph node with
follicular lymphoma; c, d, e
neck lesion with histiocytic sar-
coma; f bone marrow infiltration
with diffuse large B cell
lymphoma (patient 2; H&E)
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J Hematopathol (2009) 2:135–141 137One year later, a second recurrence with grade 3B FL was
diagnosed.HereceivedsixcoursesofR-CHOP.Athirdrelapse
with slow-growing lymph nodes and bone marrow involve-
ment was documented 3 years later and Zevalin was
administered. Thirteen years after the initial diagnosis, the
patient developed a quickly growing tumor on the left side of
the neck. The biopsy showed a diffuse infiltration with large
atypical cells with large irregular indented nuclei and
eosinophilic cytoplasm with the immunophenotype of histio-
cytes. The bone marrow showed infiltration by diffuse large B
cell lymphoma (DLBCL). The patient was treated with five
courses of DHAP, with a rapid response of the cervical tumor.
T h eD L B C Li nt h eb o n em a r r o wp r o g r e s s e dr a p i d l ya n dt h e
patient died shortly after the last DHAP course.
Fig. 2 a, b Lymph node with
follicular lymphoma (CD20 and
bcl-2, IHC); c, d, e histiocytic
sarcoma (CD14, MAF-B, and
CD1a, IHC); f bone marrow
infiltration with diffuse large B
cell lymphoma (PAX-5, IHC); g
PCR analysis of follicular lym-
phoma and histiocytic sarcoma;
h electron microscopy—detail
of Birbeck granula (patient 2)
138 J Hematopathol (2009) 2:135–141Patient 2 A 62-year-old male patient presented with nodular
lesion on the tongue and enlarged cervical lymph nodes and
was diagnosed as diffuse large cell B cell lymphoma stage
IIA. He received eight courses of R-CHOP-14 with complete
remission. One year later, a local relapse with large
pleomorphic cells and with the immunophenotype of
histiocytic cells was diagnosed. The tumor invaded the base
of the tongue, hypopharynx, and cervical lymph nodes.
Complete remission after four courses of MIME was
achieved and involved field radiotherapy with 40 Gy was
given. A second recurrence developed shortly thereafter with
similar lesions on the abdomen. The patient received no
further treatment and died of tumor progression.
Immunohistochemistry The paraffin blocks were cut at 4–
6 µm, dried overnight at 60 °C, and dewaxed in xylene. A
standard panel with 16 primary antibodies was used in both
cases (Table 1). Visualization was performed using the
EnVision® detection system (DAKO Cytomation, Denmark
A/S) according to the manufacturer’s instructions. Appropriate
positive and negative controls were used.
Fluorescent in situ hybridization (FISH) analysis Fluores-
cent in situ hybridization analysis was performed on
formalin-fixed tissue specimens, using a BCL-2 split signal
DNA probe (Y5407, DAKO Cytomation, Denmark A/S).
The slides were deparaffinized, immersed in pretreatment
buffer (K5599, DAKO Cytomation, Denmark A/S) for
10 min at 95°C, followed by pepsin pretreatment, and
dehydrated in ethanol. After a denaturation step for 10 min
at 80°C, hybridization was performed at 37°C overnight.
The next day, the slides were postwashed in saline sodium
citrate (SSC) buffer, counterstained with 4′,6-diamidino-2-
phenylindole, and evaluated using fluorescent microscope
Olympus BX61.
Polymerase chain reaction (PCR) analysis and sequencing
DNA was extracted from fresh snap-frozen tissue or
paraffin-embedded tissue using QIAmp tissue kit (Qiagen,
Hilden, Germany). Analysis of immunoglobulin heavy
chain (IgH) gene rearrangement was done using IgH
variable gene (VH) family-specific primers (VH1 trough
VH6) and VH consensus primers covering the VH
framework regions (FR) together with the consensus joining
region gene primers as described in the BIOMED-2
protocol [10]. For one sample (case 2, DLBCL), an FR-3-
specific primer was used due to the fact that only paraffin-
embedded tissue was available. IgH polymerase chain
reaction sequences were directly sequenced by using the
Big Dye terminator sequencing kit and the Genetic Analyzer
3100 (Applied Biosystems, Weiterstadt, Germany). The
sequences obtained were analyzed by comparison with the
V base database (www.vbase2.org).
As somatic hypermutation affects only the 5′ region of
affected genes, analysis of the 5′ end of the PAX5 gene was
performed using primer pairs covering exon 1 (1A and 1B);
exons 2 and 3 were used as previously described [11].
Electron microscopy
Formalin-fixed paraffin-embedded material was used. The
paraffinblockwascutandthesectionwasimmersedinxylene
and then rehydrated in alcohol. Then, the material was
a
b
 -------  F   R   3   -   I   M   G   T  ---------->_______________ CDR3 - IMGT _____________
FL                   TATTTACAAATGAACAGTTTGAAAACTGAGGACACGGCCTCCTATTACTGTACAAGAGCGGACTGTATTGCTGGTGCTTGTTATTTTGACTCT
humIGHV173           ---C-G------------C---G-G---------------TG---------G---A-  
 -------F   R   3   -   I   M   G   T  ------------> _______________ CDR3 - IMGT ____________
Histiocytic_sarcoma  TATTTGCAATTGAACAGTTTGAAAATTGAGGACACGGCCTCCTATTATTGTACAAGAGCGGACTGTATTGCTGGTGTTTGTTATTTTGACTCT
humIGHV173           ---C-----A--------C---G-GC--------------TG-----C---G---A-  
Case 2: 
   ------- F   R   3   -   I   M   G   T ---> _______________ CDR3 - IMGT ____________
DLBCL                CTGAGCTCTGTGACCGCCGCGGACACGGCCGTGTACTACTGTGCGAGATCGTCGCGCCCGATCTTCTTCTATTTCATGGACGTC
      -----------------------------------T------------
    ------- F   R   3   -   I   M   G   T ---> _______________ CDR3 - IMGT ____________
Histiocytic_sarcoma  CTAAACTCTGTGACCGCTGCGGACACGGCCGTGTACTACTGTGCGAGATCGTCGCGCCCGATCTTCTTCTATTTCATGGACGTC
humIGHV117           --G-G------------------------------T------------ 
Case 1 : 
Fig. 3 Sequences of IgH gene rearrangements. The FR3 and CDR3
region sequences are arranged with the identified patient sample at the
top, compared with the lower V base gene bank sequence with closest
homology. Dashed lines indicate that the sequence is identical to the
gene bank sequence, and a nucleotide indicates difference. a Patient 1,
follicular lymphoma compared with histiocytic sarcoma. b Patient 2,
diffuse large B cell lymphoma compared with histiocytic sarcoma
J Hematopathol (2009) 2:135–141 139immersed in cacodylate buffer for 24 h and additional
postfixation in osmium tetraoxyde for 1 h was performed.
After 1 h in uranyl acetate, the tissue was dehydrated,
embedded in EPON; ultrathin sections were cut and evalua-
tion was performed using Philips CM10 electron microscope.
Cytogenetics
Fresh tissue samples from patient 1 (two lymph node
biopsies and a biopsy from a neck tumor) were manually
minced and enzymatically treated until a suitable suspen-
sion of cells and cell clumps was obtained. After 5–7 days
of culturing, colchicine was added for the last 4 h and the
short-term cultures were harvested according to standard
protocols. The chromosomes of the dividing cells were then
G-banded and a karyotype was established in accordance
with the recommendations of the International System for
Human Cytogenetic Nomenclature.
Results and discussion
In both patients, B cell lymphoma with a germinal center
cell phenotype and t(14; 18) at first presentation was
diagnosed. A diagnosis of low-grade follicular lymphoma
with a typical morphology and immunophenotype was
established on the first biopsy in patient 1 (Fig. 1, Table 2).
Patient 2 presented with diffuse large B cell lymphoma with
germinal center cell phenotype. In both patients, the initial
lymphomas expressed CD20, PAX-5, CD10, and BCL-6
but no histiocytic markers (Fig. 2, Table 2). The recurrence
in both patients showed a different histology with large
pleomorphic cells with abundant eosinophilic cytoplasm
and large irregular nuclei with focal nuclear grooves
(Fig. 1, Table 2). The immunophenotype of these recur-
rences was also different; notably, B cell markers were lost
and a strong expression of S100, MAF-B, CD68, CD14,
and focal expression of CD1a was documented (Fig. 2,
Table 2). Epstein Barr virus-encoded RNA in situ hybrid-
ization was negative in both patients. No clinical or
morphological evidence of hemophagocytic syndrome was
noted in the two patients. Electron microscopy was only
successful in patient 2 and showed Birbeck granules
(Fig. 2). We found a clonal relationship between the tumors
with different phenotypes in both patients as documented
by similarly rearranged IgH gene sequences, respectively
(Figs. 2 and 3).
Since PAX-5 is crucial for maintaining B cell identity
and since the transformed tumors in both patients had lost
PAX-5 expression, we sequenced the 5′ part of the PAX-5
gene to detect probable aberrant somatic hypermutations
[9]. Aberrant somatic hypermutation is known to occur in B
cell lymphoma and can affect the expression of target genes
[8, 12]. However, sequence analysis of the 5′ part of PAX-5,
including exons 1, 2, and 3 of the PAX-5 gene, shows an
intact structure of the gene without somatic hypermutation.
Therefore, aberrant somatic hypermutation of PAX-5 is an
unlikely cause of loss of expression and transdifferentiation
at least in our two patients. We have not investigated
whether deletion of PAX-5 gene might explain loss of PAX-
5 expression in our two cases. However, this hypothesis
seems to be unlikely in view of the fact that the PAX-5 gene
could easily be amplified from DNA extracted from the
tumors. Morphological control of the tissues used for DNA
extraction assured that the DNA extracts were representa-
tive of the tumor and confirmed that a majority of tumor
cells were present.
Of interest, cytogenetic data were obtained in patient 1
where the follicular lymphoma as well as the histiocytic
sarcoma showed t(14; 18)(18q21). In addition, the recurrent
histiocytic sarcoma showed a more complex karyotype with
multiple deletions, duplications, and insertions. The latter
suggests that chromosomal instability is at least part of the
transformation process.
In conclusion, it is of interest that mature neoplastic B
cells may display translineage transformation. This seems
hitherto restricted to B cell lymphomas of germinal center
cell origin with t(14; 18). The mechanisms by which that
occur are yet not clear, but aberrant somatic hypermutation
of the PAX-5 gene seems to be an unlikely cause.
Conflict of interest The authors declare that they have no conflict of
interest.
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